Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae
Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 i...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1995-03, Vol.20 (3), p.671-676 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 676 |
|---|---|
| container_issue | 3 |
| container_start_page | 671 |
| container_title | Clinical infectious diseases |
| container_volume | 20 |
| creator | Haas, David W. Stratton, Charles W. Griffin, Jane P. Weeks, Lyndell Alls, Sandra C. |
| description | Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 isolates of Streptococcus pneumoniae tested was less susceptible to ceftizoxime than to either cefotaxime or ceftriaxone. The difference between minimal inhibitory concentrations (MICs) was greatest for strains moderately or fully resistant to penicillin, which at our institution represent ∼32% of all isolates of S. pneumoniae. Ten isolates with cefotaxime and ceftriaxone MICs of 2.0–6.0 μg/mL had ceftizoxime MICs of ⩾256 μg/mL. Time-kill kinetic studies assessing bactericidal activity confirmed the diminished activity of ceftizoxime against penicillin-resistant isolates of S. pneumoniae. Ceftizoxime should not be used to treat proven or suspected pneumococcal infection in areas where resistance to penicillin is prevalent. |
| doi_str_mv | 10.1093/clinids/20.3.671 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_77288746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4458400</jstor_id><sourcerecordid>4458400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-180865a239f1cc8e71091e8671e1d11823d6a6a7a1cbe9fcbd41622f8870fc6d3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EKm3hzgEkH1Bv2dqxYzvHZQsUqODAhyoulteZgEtiB9tBW349bjfaKydbep4ZzTuD0DNKVpS07NwOzrsunddkxVZC0gfomDZMVqJp6cPyJ42quGLqMTpJ6YYQShVpjtCRlI3gLT9G4cKNpUX6CR1e2-z-uHyLQ4830Gf3N-zcCNh5vAnjZKJLweMc7mDI5p4Z39270Zld8IDXP4zzKePPOcKUgw3WzglPHuYxeGfgCXrUmyHB0-U9RV_fvP6yuayuPr19t1lfVZZTlqsyphKNqVnbU2sVyJKWgioJgXYlRM06YYSRhtottL3ddpyKuu6VkqS3omOn6Gzfd4rh9wwp69ElC8NgPIQ5aSnr4nLxX5EKxVspaBHJXrQxpBSh11N0o4m3mhJ9dwy9HEPXRDNdRi0lL5be83aE7lCwbL_wlws3yZqhj8Zblw4a40ISxYr2fK_dpBziAXPeKE5IwdUeu5Rhd8Am_ipDMNnoy-vv-uKavv8mP77SH9g_2JyuEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16849761</pqid></control><display><type>article</type><title>Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae</title><source>MEDLINE</source><source>Oxford University Press Archive</source><source>JSTOR Archive Collection A-Z Listing</source><creator>Haas, David W. ; Stratton, Charles W. ; Griffin, Jane P. ; Weeks, Lyndell ; Alls, Sandra C.</creator><creatorcontrib>Haas, David W. ; Stratton, Charles W. ; Griffin, Jane P. ; Weeks, Lyndell ; Alls, Sandra C.</creatorcontrib><description>Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 isolates of Streptococcus pneumoniae tested was less susceptible to ceftizoxime than to either cefotaxime or ceftriaxone. The difference between minimal inhibitory concentrations (MICs) was greatest for strains moderately or fully resistant to penicillin, which at our institution represent ∼32% of all isolates of S. pneumoniae. Ten isolates with cefotaxime and ceftriaxone MICs of 2.0–6.0 μg/mL had ceftizoxime MICs of ⩾256 μg/mL. Time-kill kinetic studies assessing bactericidal activity confirmed the diminished activity of ceftizoxime against penicillin-resistant isolates of S. pneumoniae. Ceftizoxime should not be used to treat proven or suspected pneumococcal infection in areas where resistance to penicillin is prevalent.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/clinids/20.3.671</identifier><identifier>PMID: 7756494</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobials ; Biological and medical sciences ; Blood ; Ceftizoxime - pharmacology ; Ceftriaxone - pharmacology ; Cephalosporins ; Clinical Articles ; Kinetics ; Medical sciences ; Microbial Sensitivity Tests ; Penicillin ; Penicillin Resistance ; Pharmacology. Drug treatments ; Pneumococcal infections ; Pneumococcal meningitis ; Streptococcus pneumoniae ; Streptococcus pneumoniae - drug effects ; Time Factors</subject><ispartof>Clinical infectious diseases, 1995-03, Vol.20 (3), p.671-676</ispartof><rights>Copyright 1995 The University of Chicago</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-180865a239f1cc8e71091e8671e1d11823d6a6a7a1cbe9fcbd41622f8870fc6d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4458400$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4458400$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3467083$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7756494$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haas, David W.</creatorcontrib><creatorcontrib>Stratton, Charles W.</creatorcontrib><creatorcontrib>Griffin, Jane P.</creatorcontrib><creatorcontrib>Weeks, Lyndell</creatorcontrib><creatorcontrib>Alls, Sandra C.</creatorcontrib><title>Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 isolates of Streptococcus pneumoniae tested was less susceptible to ceftizoxime than to either cefotaxime or ceftriaxone. The difference between minimal inhibitory concentrations (MICs) was greatest for strains moderately or fully resistant to penicillin, which at our institution represent ∼32% of all isolates of S. pneumoniae. Ten isolates with cefotaxime and ceftriaxone MICs of 2.0–6.0 μg/mL had ceftizoxime MICs of ⩾256 μg/mL. Time-kill kinetic studies assessing bactericidal activity confirmed the diminished activity of ceftizoxime against penicillin-resistant isolates of S. pneumoniae. Ceftizoxime should not be used to treat proven or suspected pneumococcal infection in areas where resistance to penicillin is prevalent.</description><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobials</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Ceftizoxime - pharmacology</subject><subject>Ceftriaxone - pharmacology</subject><subject>Cephalosporins</subject><subject>Clinical Articles</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Penicillin</subject><subject>Penicillin Resistance</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumococcal infections</subject><subject>Pneumococcal meningitis</subject><subject>Streptococcus pneumoniae</subject><subject>Streptococcus pneumoniae - drug effects</subject><subject>Time Factors</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EKm3hzgEkH1Bv2dqxYzvHZQsUqODAhyoulteZgEtiB9tBW349bjfaKydbep4ZzTuD0DNKVpS07NwOzrsunddkxVZC0gfomDZMVqJp6cPyJ42quGLqMTpJ6YYQShVpjtCRlI3gLT9G4cKNpUX6CR1e2-z-uHyLQ4830Gf3N-zcCNh5vAnjZKJLweMc7mDI5p4Z39270Zld8IDXP4zzKePPOcKUgw3WzglPHuYxeGfgCXrUmyHB0-U9RV_fvP6yuayuPr19t1lfVZZTlqsyphKNqVnbU2sVyJKWgioJgXYlRM06YYSRhtottL3ddpyKuu6VkqS3omOn6Gzfd4rh9wwp69ElC8NgPIQ5aSnr4nLxX5EKxVspaBHJXrQxpBSh11N0o4m3mhJ9dwy9HEPXRDNdRi0lL5be83aE7lCwbL_wlws3yZqhj8Zblw4a40ISxYr2fK_dpBziAXPeKE5IwdUeu5Rhd8Am_ipDMNnoy-vv-uKavv8mP77SH9g_2JyuEA</recordid><startdate>19950301</startdate><enddate>19950301</enddate><creator>Haas, David W.</creator><creator>Stratton, Charles W.</creator><creator>Griffin, Jane P.</creator><creator>Weeks, Lyndell</creator><creator>Alls, Sandra C.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19950301</creationdate><title>Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae</title><author>Haas, David W. ; Stratton, Charles W. ; Griffin, Jane P. ; Weeks, Lyndell ; Alls, Sandra C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-180865a239f1cc8e71091e8671e1d11823d6a6a7a1cbe9fcbd41622f8870fc6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobials</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Ceftizoxime - pharmacology</topic><topic>Ceftriaxone - pharmacology</topic><topic>Cephalosporins</topic><topic>Clinical Articles</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Penicillin</topic><topic>Penicillin Resistance</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumococcal infections</topic><topic>Pneumococcal meningitis</topic><topic>Streptococcus pneumoniae</topic><topic>Streptococcus pneumoniae - drug effects</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haas, David W.</creatorcontrib><creatorcontrib>Stratton, Charles W.</creatorcontrib><creatorcontrib>Griffin, Jane P.</creatorcontrib><creatorcontrib>Weeks, Lyndell</creatorcontrib><creatorcontrib>Alls, Sandra C.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haas, David W.</au><au>Stratton, Charles W.</au><au>Griffin, Jane P.</au><au>Weeks, Lyndell</au><au>Alls, Sandra C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1995-03-01</date><risdate>1995</risdate><volume>20</volume><issue>3</issue><spage>671</spage><epage>676</epage><pages>671-676</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>Previous reports documenting the essentially identical spectra of activity of ceftizoxime, cefotaxime, and ceftriaxone prompted our hospital formulary committee to replace the latter two drugs with ceftizoxime on the basis of cost differences. However, we subsequently observed that every one of 60 isolates of Streptococcus pneumoniae tested was less susceptible to ceftizoxime than to either cefotaxime or ceftriaxone. The difference between minimal inhibitory concentrations (MICs) was greatest for strains moderately or fully resistant to penicillin, which at our institution represent ∼32% of all isolates of S. pneumoniae. Ten isolates with cefotaxime and ceftriaxone MICs of 2.0–6.0 μg/mL had ceftizoxime MICs of ⩾256 μg/mL. Time-kill kinetic studies assessing bactericidal activity confirmed the diminished activity of ceftizoxime against penicillin-resistant isolates of S. pneumoniae. Ceftizoxime should not be used to treat proven or suspected pneumococcal infection in areas where resistance to penicillin is prevalent.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>7756494</pmid><doi>10.1093/clinids/20.3.671</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1995-03, Vol.20 (3), p.671-676 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77288746 |
| source | MEDLINE; Oxford University Press Archive; JSTOR Archive Collection A-Z Listing |
| subjects | Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobials Biological and medical sciences Blood Ceftizoxime - pharmacology Ceftriaxone - pharmacology Cephalosporins Clinical Articles Kinetics Medical sciences Microbial Sensitivity Tests Penicillin Penicillin Resistance Pharmacology. Drug treatments Pneumococcal infections Pneumococcal meningitis Streptococcus pneumoniae Streptococcus pneumoniae - drug effects Time Factors |
| title | Diminished Activity of Ceftizoxime in Comparison to Cefotaxime and Ceftriaxone Against Streptococcus pneumoniae |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A55%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diminished%20Activity%20of%20Ceftizoxime%20in%20Comparison%20to%20Cefotaxime%20and%20Ceftriaxone%20Against%20Streptococcus%20pneumoniae&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Haas,%20David%20W.&rft.date=1995-03-01&rft.volume=20&rft.issue=3&rft.spage=671&rft.epage=676&rft.pages=671-676&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/clinids/20.3.671&rft_dat=%3Cjstor_proqu%3E4458400%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16849761&rft_id=info:pmid/7756494&rft_jstor_id=4458400&rfr_iscdi=true |